Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain May 14, 2024-Brixton Biosciences
BRIXTON BIOSCIENCES’ COOLIO™ THERAPY GRANTED BREAKTHOUGH DEVICE DESIGNATION BY FDA October 26, 2023-Brixton Biosciences
